TY  - JOUR
T1  - Immunohistochemical Detection of Alpha-Methyl-Co-Racemase
(AMACR) in Adenocarcinoma of Prostate
AU - Yousif Babiker, Ali AU - Abdelaziz, Mohammed S. AU - Mohagir, Hagir E. AU - Alsahli, Mohamed A. AU - Almatroodi, Saleh A. AU - Rahmani, Arshad H. 
JO  - Research Journal of Medical Sciences
VL  - 10
IS  - 6
SP  - 707
EP  - 710
PY  - 2016
DA  - 2001/08/19
SN  - 1815-9346
DO  - rjmsci.2016.707.710
UR  - https://makhillpublications.co/view-article.php?doi=rjmsci.2016.707.710
KW  - Prostate tumor
KW  -AMACR expression IHC
KW  -adenocarcinoma
KW  -vital factors
KW  -Saudi Arabia
AB  - The aim of study was to evaluate the expression pattern of Alpha-methylacyl-CoA Racemase
(AMACR) in prostate tumors. In order to examine the relationship between AMCAR expression and tumor, we
analyzed a total of 10 cases of benign prostatic hyperplasia and 20 cases of prostate adenocarcinoma .
Expressions pattern of AMCAR were analysed and found that only one case (10%) of benign prostatic
hyperplasia showed expression whereas 19 cases (95%) of prostate adenocarcinoma showed expression at
different levels of intensity. The difference in expression pattern among benign prostatic hyperplasia and
prostate adenocarcinoma was statically significant (p>0.05). Expression profile were further categorised
according to grade of the tumor and found that AMCAR was expressed in 4 (100%), 6 (100%) and 9 (90%) in
well, moderate and poor differentiated prostate adenocarcinoma respectively. This difference of expression
among the different types of grade was statistically insignificant (p>0.05). Our results concluded that AMCAR
is a valuable diagnostic and prognostic marker of prostate cancer and one of the vital factors in pathogenesis
of prostrate adenocarcinoma.
ER  -